In AML, TIGIT blockade therapy can effectively reverse TIGIT-mediated suppression of IFN-γ secretion in NK cells while augmenting their cytotoxic activity, thus offering a promising therapeutic target for AML treatment [164]. The gene discussed is TIGIT; the disease is acute myeloid leukemia.